VistaGen Therapeutics (NASDAQ:VTGN) Rating Increased to Hold at Wall Street Zen

Key Points

• VistaGen Therapeutics has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, indicating a shift in analysts' perception of the company's stock.
• The stock experienced a 12.2% gain, opening at $3.31, with a market capitalization of approximately $101.55 million.
• Institutional investors own 78.39% of VistaGen's stock, with notable recent increases in holdings from firms such as Jane Street Group and ADAR1 Capital Management.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

Separately, William Blair reiterated an "outperform" rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 18th.

VistaGen Therapeutics Trading Up 12.2%

Shares of NASDAQ VTGN opened at $3.31 on Friday. The firm's 50-day moving average price is $2.50 and its 200-day moving average price is $2.51. VistaGen Therapeutics has a 1-year low of $1.90 and a 1-year high of $3.79. The firm has a market capitalization of $101.55 million, a P/E ratio of -1.86 and a beta of 0.40.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share for the quarter, meeting the consensus estimate of ($0.47). VistaGen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 74.06%. The business had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.22 million. Equities research analysts forecast that VistaGen Therapeutics will post -1.77 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in VistaGen Therapeutics in the 2nd quarter worth approximately $190,000. Stempoint Capital LP boosted its holdings in VistaGen Therapeutics by 2.0% in the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company's stock valued at $4,827,000 after purchasing an additional 46,700 shares during the period. Marshall Wace LLP bought a new position in VistaGen Therapeutics in the 2nd quarter valued at $69,000. AdvisorShares Investments LLC boosted its holdings in VistaGen Therapeutics by 27.7% in the 2nd quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company's stock valued at $406,000 after purchasing an additional 44,000 shares during the period. Finally, ADAR1 Capital Management LLC boosted its holdings in VistaGen Therapeutics by 246.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company's stock valued at $1,052,000 after purchasing an additional 299,304 shares during the period. 78.39% of the stock is owned by institutional investors.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.